When will CagriSema be approved? Where the FDA decision stands

TL;DR: the short version

• CagriSema is a weekly weight-loss injection that combines two medicines: semaglutide (a GLP-1 medicine, which copies a gut hormone that helps you feel full) and cagrilintide (a long-acting copy of amylin, another fullness hormone).
• It is not approved yet. Novo Nordisk asked the FDA to approve it on 18 December 2025, and no decision has been announced as of 26 October 2026.
• Novo Nordisk still expects a decision in the last quarter of 2026 (by 31 December), but no official decision date (the "PDUFA date") has been made public and no FDA advisory committee meeting has been announced. Exact dates you see online are estimates.
• If approved, it would be the first weekly injection to pair a GLP-1 medicine with an amylin medicine.
• You don't have to wait. Semaglutide and tirzepatide are approved and available now, and a physician can help you decide whether to start one or wait. The options are set out further down this page.

Educational content, not medical advice. No doses or protocols appear. Weight-management medicines are prescription medicines.

Updated October 2026: status re-checked on 26 October 2026. Still under FDA review and not approved; Novo Nordisk's Q4 2026 guidance stands; no public PDUFA date and no advisory committee announced. The window closes on 31 December, so this page will be re-checked in the first week of January 2027 whether or not news lands.

---

CagriSema is one of the most anticipated weight-loss medicines of the decade, and the question people ask most is simple: when can I get it? The honest answer, as of 26 October 2026, is that no decision has been announced. One is expected within weeks, but nobody outside Novo Nordisk and the FDA knows the exact date. This page explains what is actually known, what the dates you see online really mean, and what to do in the meantime.

What CagriSema is

CagriSema is a fixed-dose combination of two medicines in one weekly injection:

• Semaglutide, the GLP-1 medicine in Wegovy and Ozempic, which reduces appetite and improves blood sugar control.
• Cagrilintide, a long-acting version of amylin, a hormone released alongside insulin after meals that signals fullness through a separate pathway (see the cagrilintide compound reference).

The idea is that acting on two satiety pathways at once produces more weight loss than GLP-1 alone. Because the two are combined in set proportions, the FDA has to evaluate CagriSema as a product in its own right, even though semaglutide is already approved. The full picture of how it works and what the trials showed is in CagriSema explained.

Where the FDA review stands

What a PDUFA date is, and why there isn't a public one

When the FDA accepts an application for review, it sets a goal date by which it commits to reach a decision. This is known as the PDUFA date, after the law that created the user-fee review system.

Two things about it are widely misunderstood.

It is a deadline for a decision, not a promise of approval. On the PDUFA date the FDA either approves the drug or issues a "complete response letter" setting out what it needs before it can approve. Both count as meeting the date.

The FDA does not normally publish it. PDUFA dates become public only when the company discloses them, usually in a press release or investor update. Novo Nordisk has not disclosed one for CagriSema. So any exact date you see quoted, including the "October 2026" figure repeated in some trade coverage, is an estimate unless it can be traced to a company announcement.

For more on the difference between a medicine being filed, approved and actually available, see filed, approved, available.

Where "late 2026" comes from

The expected timing is simple arithmetic. A standard FDA review takes roughly 10 to 12 months from submission. Starting from 18 December 2025, that lands between October and December 2026. Reviews can run longer if the FDA extends the clock or asks for more information, which is why early 2027 is also possible.

Novo Nordisk's own guidance matches this window. It is a reasonable expectation, and it is the best estimate available, but it is a company forecast rather than an official FDA date.

What about the head-to-head trial against tirzepatide?

In February 2026, the REDEFINE 4 trial compared CagriSema directly with tirzepatide (Zepbound). CagriSema reached 23.0% average weight loss against 25.5% for tirzepatide at 84 weeks, and missed its main goal of showing it was not meaningfully less effective (non-inferiority).

Two points matter for the approval question:

• REDEFINE 4 was not part of the application. It reported after the December 2025 filing, which rests on REDEFINE 1 and 2.
• The FDA does not approve drugs by ranking them against competitors. Approval turns on whether the submitted evidence shows the drug is effective and safe for its intended use, and whether it can be manufactured reliably. Around 20% or more average weight loss is a substantial result on any measure.

How CagriSema compares with other options is covered in GLP-1 generations compared and new weight-loss drugs for 2026 and 2027.

What happens after a decision

If the FDA approves CagriSema, several steps still come before most people can get it:

1. US launch. Novo Nordisk sets pricing and supply, typically within weeks to months of approval.
2. Other countries. Each regulator reviews separately. In Southeast Asia, approval by NPRA in Malaysia, HSA in Singapore, the Thai FDA or BPOM in Indonesia follows its own timeline and often lags the US by a year or more. See GLP-1 access in Malaysia.
3. Supply. New GLP-1 medicines have often been supply-limited at launch.

If the FDA issues a complete response letter instead, the timeline resets depending on what additional information is requested.

If you don't want to wait: options to discuss with a physician

For most people considering CagriSema, the realistic question is not "when will it arrive" but "should I start something now or wait?" These are conversations to have with a physician, not prescriptions. Two highly effective medicines are already approved and available:

• Semaglutide, the same GLP-1 component that is in CagriSema. See semaglutide explained.
• Tirzepatide, a dual GLP-1 and GIP agonist, which outperformed CagriSema in the head-to-head trial. See tirzepatide explained.

A third name comes up often in the same conversations, and it is a different case:

• Retatrutide works on three hormone signals: GLP-1, GIP and glucagon (a hormone that affects how the body uses energy). It is investigational: still in clinical trials and not approved anywhere. Eli Lilly has said it plans to apply for US approval in early 2027, so it is further from approval than CagriSema. Its page explains its current status, and retatrutide explained covers the science.

Starting one of these now does not rule out switching later if CagriSema is approved and suits you better. Vivre's metabolic programme, V-03 Metabolic, is built around baseline bloodwork and ongoing monitoring, so the choice is made on your data rather than a release date. Baseline testing is described in what to test. Cagrilintide on its own is also investigational and not approved; its compound page explains its status.

Frequently asked questions

When will CagriSema be available? Novo Nordisk expects an FDA decision by late 2026. If it is approved, US launch would follow, likely late 2026 or early 2027. Availability in other countries depends on each national regulator and usually comes later.

What is CagriSema's PDUFA date? No PDUFA date has been made public. The FDA does not usually publish these dates; companies disclose them, and Novo Nordisk has not. Estimates such as "October 2026" are unofficial.

Did losing the head-to-head against tirzepatide hurt CagriSema's chances? Not directly. That trial was not part of the application under review, and the FDA assesses whether a drug is effective and safe on its own evidence, not whether it beats a competitor. The result matters more for how doctors and patients choose between options once it is approved.

Is there a legitimate way to get CagriSema before approval? No. Until it is approved, CagriSema cannot be prescribed and there is no legitimate compounded version. Approved alternatives such as semaglutide and tirzepatide are available now as prescription medicines, and your own doctor can talk you through them.

---

Related reading

• CagriSema explained: how it works and what the trials showed
• Cagrilintide and the REDEFINE trials: the amylin half of the combination
• New weight-loss drugs for 2026 and 2027: the full pipeline
• GLP-1 generations compared: where CagriSema fits
• Filed, approved, available: why those are three different dates

Part of The Complete Guide to GLP-1 Weight-Loss Drugs.

Where Vivre Labs fits

Vivre Labs offers semaglutide and tirzepatide, both approved prescription medicines for weight management, and lists cagrilintide and retatrutide with their investigational status stated. Whichever way you lean, we recommend starting with baseline bloodwork, so the decision rests on your numbers rather than a release date.

Vivre Labs publishes educational content and does not provide medical advice. CagriSema is investigational and not approved by the FDA or any other regulator; no FDA decision had been announced as of 26 October 2026. Regulatory timelines change; this page will be updated when a decision is announced. No doses or protocols appear on this page. Last reviewed: October 2026.

References

• Novo Nordisk, "Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management," December 2025. <https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html>
• PharmExec, "Novo Nordisk Submits NDA to FDA for CagriSema." <https://www.pharmexec.com/view/novo-nordisk-submits-nda-fda-cagrisema>
• Novo Nordisk, Form 6-K FY2026 (US regulatory milestones). <https://www.sec.gov/Archives/edgar/data/0000353278/000117184326003645/f6k_052226.htm>
• CNBC, "What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss," 24 February 2026. <https://www.cnbc.com/2026/02/24/healthy-returns-whats-next-for-novo-nordisks-obesity-drug-cagrisema.html>
• Drugs.com, CagriSema FDA approval status. <https://www.drugs.com/history/cagrisema.html>
• Ad-hoc News, "Novo Nordisk's Pipeline Has Three Clocks Ticking," 23 October 2026: company still expects an FDA decision on CagriSema in Q4 2026; CagriSema remains investigational; no PDUFA date given. <https://www.ad-hoc-news.de/boerse/news/unternehmensnachrichten/novo-nordisk-s-pipeline-has-three-clocks-ticking-and-none-of-them-is-a-done-deal/70395911>